Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. (Q46946613)

26 December 2017

title

Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. (English)

1 reference

26 December 2017

1 reference

Henry Milgrom

1

1 reference

26 December 2017

Barbara Kittner

series ordinal

2

1 reference

26 December 2017

Robert Lanier

series ordinal

3

1 reference

26 December 2017

Frank C Hampel

series ordinal

4

1 reference

26 December 2017

publication date

1 October 2007

1 reference

26 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

26 December 2017

volume

99

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

page(s)

358-363

1 reference

26 December 2017

Asthma and allergic rhinitis among Finnish adolescents in 1977-1991

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Prevalence of asthma, allergic rhinitis and dermatitis in primary school children in Uasin Gishu district, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Münster, Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Complications of allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Pediatric allergic rhinitis and comorbid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Overview of comorbid associations of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Rhinitis and asthma: evidence for respiratory system integration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Quality of life in adults and children with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Advances in allergy management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

First do no harm: managing antihistamine impairment in patients with allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Safety of fexofenadine in children treated for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

Economic impact and quality-of-life burden of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960553-4

7 January 2021

10.1016/S1081-1206(10)60553-4

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ft6d4dhpjvculnsf67hn5pcch4

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_ft6d4dhpjvculnsf67hn5pcch4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ft6d4dhpjvculnsf67hn5pcch4

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/ft6d4dhpjvculnsf67hn5pcch4

1 reference

30 July 2022